Beneficial effects of 2 years of administration of parenteral testosterone undecanoate on the metabolic syndrome and on non-alcoholic liver steatosis and C-reactive protein

Hormone Molecular Biology and Clinical Investigation

Volumn 1, Issue 1, 2010, Pages 27-33

  Haider, Ahmad ^a   Gooren, Louis J G ^b   Padungtod, Pawin ^c   Saad, Farid ^d,d,e  

^a Private Urology Praxis   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d BAYER PHARMA AG   (Germany)

^e GULF MEDICAL UNIVERSITY   (United Arab Emirates)

Author keywords

aging; liver steatosis; metabolic syndrome; testosterone

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE UNDECANOATE; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLADDER CAPACITY; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DRUG DOSE REDUCTION; EDUCATION PROGRAM; FEMALE; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGONADISM; INTERNATIONAL PROSTATE SYMPTOM SCORE; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROSTATE VOLUME; PROTEIN BLOOD LEVEL; REFERENCE VALUE; TESTOSTERONE BLOOD LEVEL; THERAPY EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 81255202840     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2010.002     Document Type: Article

References (41)

1. Kaufman JM., Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833-76.
2. Araujo AB., O'Donnell AB., Brambilla DJ., Simpson WB., Long-cope C., Matsumoto AM., McKinlay JB. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89:5920-6.
3. Liu PY., Beilin J., Meier C., Nguyen TV., Center JR., Leedman PJ., Seibel MJ., Eisman JA., Handelsman DJ. Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. J Clin Endocrinol Metab 2007;92:3599-603.
4. Shores MM., Moceri VM., Gruenewald DA., Brodkin KI., Mat-sumoto AM., Kivlahan DR. Low testosterone is associated with decreased function and increased mortality risk: a preliminary study of men in a geriatric rehabilitation unit. J Am Geriatr Soc 2004;52:2077-81.
5. Shores MM., Matsumoto AM., Sloan KL., Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006;166:1660-5.
6. Laughlin GA., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68-75.
7. Khaw KT., Dowsett M., Folkerd E., Bingham S., Wareham N., Luben R., Welch A., Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007;116:2694-701.
8. Araujo A., Kupelian V., Page ST., Handelsman DJ., Bremner WJ., McKinlay JB. Sex steroids and all-cause mortality and cause-specific mortality in men. Arch Intern Med 2007;167:1252-60.
9. Mohr BA., Bhasin S., Link CL., O'Donnell AB., McKinlay JB. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol 2006;155:443-52.
10. Rodriguez A., Muller DC., Metter EJ., Maggio M., Harman SM., Blackman MR., Andres R. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007;92:3568-72.
11. Kaplan SA., Meehan AG., Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol 2006;176:1524-7; discussion 7-8.
12. Allan CA., Strauss BJ., Burger HG., Forbes EA., McLachlan RI. The association between obesity and the diagnosis of androgen deficiency in symptomatic ageing men. Med J Aust 2006;185: 424-7.
13. Kalyani RR., Dobs AS. Androgen deficiency., diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007;14:226-34.
14. Cornier MA., Dabelea D., Hernandez TL., Lindstrom RC., Steig AJ., Stob NR., van Pelt RE., Wang H., Eckel RH. The metabolic syndrome. Endocr Rev 2008;29:777-822.
15. Stellato RK., Feldman HA., Hamdy O., Horton ES., McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care 2000;23:490-4.
16. Laaksonen DE., Niskanen L., Punnonen K., Nyyssonen K., Tuo-mainen TP., Valkonen VP., Salonen R., Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036-41.
17. Smith MR., Lee H., Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006;91:1305-8.
18. Basaria S., Muller DC., Carducci MA., Egan J., Dobs AS. Hyper-glycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006;106: 581-8.
19. Yialamas MA., Dwyer AA., Hanley E., Lee H., Pitteloud N., Hayes FJ. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007;92:4254-9.
20. Rector RS., Thyfault JP., Wei Y., Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 2008;14:185-92.
21. Stefan N., Kantartzis K., Haring HU. Causes and metabolic consequences of fatty liver. Endocr Rev 2008;29:939-60.
22. Musso G., Gambino R., Bo S., Uberti B., Biroli G., Pagano G., Cassader M. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese non-diabetic subjects. Diabetes Care 2008;31:562-8.
23. Kotronen A., Westerbacka J., Bergholm R., Pietilainen KH., Yki-Järvinen H. Liver fat in the metabolic syndrome. J Clin Endo-crinol Metab 2007;92:3490-7.
24. Kerner A., Avizohar O., Sella R., Bartha P., Zinder O., Markiewicz W., Levy Y., Brook GJ., Aronson D. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005;25:193-7.
25. Allan CA., Strauss BJ., Burger HG., Forbes EA., McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in non-obese aging men. J Clin Endocrinol Metab 2008;93:139-46.
26. Munzer T., Harman SM., Hees P., Shapiro E., Christmas C., Bel-lantoni MF., Stevens TE., O'Connor KG., Pabst KM., St Clair C., Sorkin JD., Blackman MR. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J Clin Endocrinol Metab 2001; 86:3604-10.
27. Schroeder ET., Zheng L., Ong MD., Martinez C., Flores C., Stewart Y., Azen C., Sattler FR. Effects of androgen therapy on adipose tissue and metabolism in older men. J Clin Endocrinol Metab 2004;89:4863-72.
28. La Vignera S., Calogero AE., D'Agata R., Di Mauro M., Tumino S., Condorelli R., Lanzafame F., Finocchiaro C., Giammusso B., Vicari E. Testosterone therapy improves the clinical response to conventional treatment for male patients with metabolic syndrome associated to late onset hypogonadism. Minerva Endo-crinol 2008;33:159-67.
29. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285: 2486-97.
30. West B, Welch K., Galecki A. Linear mixed models: a practical guide using statistical software. New York, NY, USA: Chapman Hall/CRC, 2007.
31. Dawson B., Trapp R. Basic and clinical biostatistics, 4th edn. Boston, MA, USA: McGraw-Hill, 2004.
32. Saad F., Gooren LJ., Haider A., Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 2008;29:102-5.
33. Esmaillzadeh A., Mirmiran P., Azizi F. Metabolic abnormalities identified by anthropometric measures in elderly men. Am J Clin Nutr 2006;83:173-4 (author reply 4).
34. Allan CA., Strauss BJ., Burger HG., Forbes EA., McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocri-nol Metab 2008;93:139-46.
35. Marin P., Oden B., Bjorntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1995;80:239-43.
36. Page ST., Amory JK., Bowman FD., Anawalt BD., Matsumoto AM., Bremner WJ., Tenover JL. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005;90:1502-10.
37. Saad F., Gooren L., Haider A., Yassin A. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl 2007;53:353-7.
38. Yassin AS., Saad F. Erectile dysfunction, metabolic syndrome, hypogonadism are intertwined. J Urol 2007;177:288.
39. Saad F., Gooren L., Haider A., Yassin A. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome. Andro-logia 2008;40:44-8.
40. Pitteloud N., Hardin M., Dwyer AA., Valassi E., Yialamas M., Elahi D., Hayes FJ. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005;90:2636-41.
41. Svartberg J., Agledahl I., Figenschau Y., Sildnes T., Waterloo K., Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008;20:378-87.